scholarly journals Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.

2013 ◽  
Vol 7 (7-8) ◽  
pp. 544 ◽  
Author(s):  
Rafal Turo ◽  
Samer Jallad ◽  
William Richard Cross ◽  
Stephen Prescott
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Estrogen Therapy ◽  
Hormone Ablation ◽  
Castrate Resistant ◽  
Male To Female

The incidence of prostate cancer in transsexual patients is very low with only few reported cases. Many years before presenting with prostate cancer, these patients receive hormone ablation as a part of their gender therapy. Their disease is already defined as castrate resistant, and the treatment and follow-up of such patients remains a challenge. We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.

scholarly journals Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Ayun Cassell ◽  
Bashir Yunusa ◽  
Mohamed Jalloh ◽  
Medina Ndoye ◽  
Mouhamadou M. Mbodji ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Cost Effective ◽  
Androgen Deprivation ◽  
Sub Saharan Africa ◽  
International Agency ◽  
Castrate Resistant Prostate Cancer ◽  
Sub Saharan ◽  
Castrate Resistant

The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.

scholarly journals Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 12477-12488 ◽  
Author(s):  
Hojjat Ahmadzadehfar ◽  
Elisabeth Eppard ◽  
Stefan Kürpig ◽  
Rolf Fimmers ◽  
Anna Yordanova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Response ◽  
Radioligand Therapy ◽  
Castrate Resistant

Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4687-4687 ◽  
Author(s):  
D. R. Shepard ◽  
A. Weil ◽  
J. A. Garcia ◽  
R. Dreicer ◽  
D. Raghavan
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Elderly Men ◽  
Castrate Resistant
Sign in / Sign up

Export Citation Format

Share Document